online games laptop
College Football Playoff live rankings: Updated 12-team bracket revealed in fourth CFP poll of 2024 | Sporting NewsThe Audible: Bill Belichick and the new college football landscape
As previously announced, Abpro also has entered into a Standby Equity Purchase Agreement with Yorkville (the "SEPA”) pursuant to which Abpro has the right, but not the obligation, to issue up to $50 million in shares of its common stock to Yorkville upon registration of such shares, provided that no balance is outstanding on any promissory note to Yorkville (currently $3 million dollars outstanding). Among other restrictions and conditions set forth in the SEPA, the number of shares Abpro may request may not exceed the average of the daily traded amount of its shares of common stock during the five consecutive trading days preceding such request, and shall not cause Yorkville's ownership to exceed 4.99% of the then outstanding common stock of Abpro, and the maximum amount of shares issued under the SEPA cannot exceed 19.99% of the outstanding common stock of Abpro without prior shareholder approval. Upon registration of the shares subject to the SEPA, Abpro has the right to receive financing for an additional $2 million. As previously announced, Abpro also has entered into a forward purchase agreement for the sale of up to 500,000 shares of common stock. Abpro believes that the various financings should significantly improve Abpro's financial flexibility as it advances the development of its pipeline of its next-generation antibody therapies. "Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat oncology and ophthalmology indications,” said Ian Chan, CEO and co-founder of Abpro. "The funds are expected to help accelerate the advancement of our pipeline to clinical trials. The financing will also provide the foundation for ongoing development of novel immunotherapies and next-generation antibody treatments in our pipeline with the aim of improving the lives of patients in need.” Abpro is advancing its pipeline of next-generation antibody therapies for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These next-generation antibodies are developed using Abpro's proprietary DiversImmune® platform, which creates antibody therapies against traditionally difficult targets. Abpro has partnered with Celltrion , a leading South Korean pharmaceutical company, in an exclusive global collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancers. Soo Young Lee, Senior Vice President and Head of the New Drug Division of Celltrion Inc. and a member of Abpro's Board of Directors, remarked, "Abpro's ABP 102 drug candidate has shown preclinical data indicating the potential for better efficacy and less toxicity. We look forward to working closely with Abpro to advance ABP 102 into clinical trials.” Tony Eisenberg, who serves as a Director of Abpro, and had served as Chief Strategy Officer of ACAB prior to the business combination, added, "It's an honor to be part of Abpro and the groundbreaking work they are doing. The Atlantic Coastal team is excited to have successfully completed this business combination with Abpro and to work with the Abpro management team to execute their long-term operational and strategic objectives as they develop next-generation antibody therapies with the potential to save lives and generate real return for investors.” Abpro's Chairperson, Miles Suk, stated, "As the chairperson of the board, I am honored to guide Abpro through this landmark achievement. This listing marks a new chapter of growth and opportunity, and we remain committed to delivering sustainable value to our shareholders." About Abpro Abpro's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro has partnered with Celltrion, which is a leading South Korean biotechnology company, ranked top 25 in the world by market capitalization, in an exclusive collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancer. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.com . Forward Looking Statements This press release contains certain "forward-looking statements” within the meaning of the "safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe,” "project,” "expect,” "anticipate,” "estimate,” "intend,” "strategy,” "aim,” "future,” "opportunity,” "plan,” "may,” "should,” "will,” "would,” "will be,” "will continue,” "will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; Abpro's ability to raise additional capital; the outcome of judicial proceedings to which Abpro or its subsidiaries is, or may become a party; failure to realize the anticipated benefits of the Business Combination, including difficulty in, or costs associated with, integrating the businesses of ACAB and Abpro; risks related to the rollout of Abpro's business and the cost and timing of expected business milestones; the effects of competition on Abpro's future business; and those factors discussed in Abpro's public filings under the heading "Risk Factors,” and other documents of Abpro filed, or to be filed, with the SEC. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the "Risk Factors” section of Abpro's public filings and other documents to be filed by Abpro from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward- looking statements, and while Abpro may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Abpro does not give any assurance that Abpro will achieve its expectations. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. CONTACT: Contacts Company: [email protected] Investors: [email protected] Media: Jessica Yingling, Ph.D., Little Dog Communications Inc. [email protected]
Barcelona, Bayern, and Arsenal secured vital wins as Manchester City’s defensive woes continued in a dramatic Champions League matchday. New Delhi: The UEFA Champions League delivered another thrilling matchday with exciting clashes and dramatic turnarounds across Europe. Teams battled fiercely to secure vital points as the league phase nears its conclusion. From commanding wins by Atalanta and Arsenal to a resilient fightback by Feyenoord against Manchester City, the action had it all. Standout performances included Charles De Ketelaere’s brilliance for Atalanta in their 6-1 demolition of Young Boys, while Bayern Munich edged past PSG with a gritty 1-0 victory. Elsewhere, Barcelona and Bayer Leverkusen showcased their dominance, while Inter Milan’s narrow win over RB Leipzig solidified their top spot. However, Manchester City’s six-match winless streak continued as they let a three-goal lead slip in a dramatic 3-3 draw. Manchester City 3-3 Feyenoord 😳❗️ From 3-0 to 3-3! pic.twitter.com/i38Xid1XS8 — Fabrizio Romano (@FabrizioRomano) November 26, 2024 Manchester City’s struggles continued as they threw away a three-goal lead to draw 3-3 against Feyenoord in a dramatic Champions League encounter. This result extends Pep Guardiola’s winless run to six matches, the worst streak of his managerial career. City appeared to be in full control when Erling Haaland struck twice, either side of Ilkay Gundogan’s deflected volley. The home side dominated for most of the match, with Feyenoord offering little resistance until the final 15 minutes. Guardiola even introduced Kevin De Bruyne and youngsters James McAtee and Jahmai Simpson-Pusey, seemingly confident the game was sealed. But Feyenoord fought back. Anis Hadj Moussa punished a Josko Gvardiol error to pull one back. Substitute Santiago Gimenez then made it 3-2 with a close-range finish, before David Hancko stunned the Etihad with a late equaliser. Defensive lapses and Ederson’s poor showing left City reeling. The draw halts a five-game losing streak but feels like a defeat. City now sit 15th in the Champions League table, with their form raising serious concerns. A trip to Anfield looms on Sunday, where defeat could widen the gap to the league leaders. Guardiola and his side are now staring at a genuine crisis. FC Barcelona 3-0 Brest ⭐️ FULL TIME!!! ⭐️ pic.twitter.com/gWM5mFGQwX — FC Barcelona (@FCBarcelona) November 26, 2024 Barcelona secured their fourth consecutive UEFA Champions League League Phase win with a convincing 3-0 triumph over Brest at the Montjuic Olympic Stadium. The victory solidified their place in the top eight and eased concerns after a recent dip in form. Though it took 65 minutes to settle into a comfortable lead, Hansi Flick’s side showcased their dominance and controlled the match throughout. The game started brightly for Barça, who took the lead after just ten minutes. Robert Lewandowski calmly converted from the penalty spot following a foul by Brest goalkeeper Marco Bizot, marking his 100th Champions League goal. The hosts dictated the tempo, pressing high and recovering possession quickly, but struggled with their decision-making in the final third. Despite creating several chances, they couldn’t add to their lead before the break, with Brest’s defence and Bizot making crucial interventions. In the second half, Barcelona continued to dominate possession and create opportunities but found Brest difficult to break down. Dani Olmo came close, only to see his effort cleared off the line. Persistence paid off on 65 minutes when Gerard Martín’s pinpoint pass found Olmo, who evaded defenders and slotted home to double the advantage. Barça remained in control and sealed the win in stoppage time. Alejandro Balde delivered a perfect assist for Lewandowski, who finished with style to complete his brace. While the scoreline could have been more emphatic given their dominance, this comprehensive performance takes Barcelona a step closer to the Champions League Round of 16. In the second half, Barcelona continued to dominate possession and create opportunities but found Brest difficult to break down. Dani Olmo came close, only to see his effort cleared off the line. Persistence paid off on 65 minutes when Gerard Martín’s pinpoint pass found Olmo, who evaded defenders and slotted home to double the advantage. Barca remained in control and sealed the win in stoppage time. Alejandro Balde delivered a perfect assist for Lewandowski, who finished with style to complete his brace. While the scoreline could have been more emphatic given their dominance, this comprehensive performance takes Barcelona a step closer to the Champions League Round of 16. Bayern Munich 1-0 Paris St. Germain 🔔 FULL TIME – Victory at home! +3 in the #UCL 👏❤️ #FCBayern #MiaSanMia | #FCBPSG #UCL pic.twitter.com/BYE23dXXih — FC Bayern (@FCBayernEN) November 26, 2024 Bayern Munich edged out Paris Saint-Germain 1-0 in a gritty encounter on Tuesday evening at the Allianz Arena in matchday five of the 2024/25 UEFA Champions League League Phase. Vincent Kompany’s side earned a vital three points thanks to Kim Min-jae’s first-half header, moving them closer to a top-eight finish while delivering a blow to PSG’s chances. Kompany fielded a strong XI featuring Manuel Neuer, Raphael Guerreiro, Dayot Upamecano, Kim Min-jae, and Alphonso Davies in defence; Joshua Kimmich and Leon Goretzka in midfield; and Michael Olise, Jamal Musiala, Kingsley Coman, and Harry Kane in attack. The opening minutes saw Bayern miss a golden chance as Musiala’s close-range effort was saved, while PSG immediately countered but failed to capitalise through Ousmane Dembele. Both sides exchanged half-chances, with Coman narrowly missing after a brilliant solo run and PSG’s Warren Zaire-Emery firing wide from a promising position. The breakthrough came just after the half-hour mark when Kim Min-jae rose highest to head home following a scrambled PSG clearance from a corner. Bayern nearly doubled their lead moments later, but Coman’s audacious lob bounced onto the roof of the net. As the half concluded, Leroy Sane forced a save from Gianluigi Donnarumma, with Bayern heading into the break one goal up. The second half started with drama as PSG’s Dembele received a second yellow card for a foul on Davies, reducing the French champions to 10 men. Despite the numerical advantage, Bayern found PSG difficult to break down and missed opportunities to extend their lead. Musiala struck the post after a superb solo effort, while substitute Michael Olise came close immediately after his introduction but couldn’t find the finish. In the dying moments, Serge Gnabry stretched for a Thomas Muller cross but failed to convert, though it mattered little as Bayern secured the win. The result puts them in 11th place, just a point off the top eight, with a favourable schedule remaining. This defeat ends PSG’s hopes of progressing to the knockout stages. Inter Milan 1-0 RB Leipzig ANOTHER BIG WIN 🖤💙 #ForzaInter #InterRBL #UCL pic.twitter.com/4ttb7pWpNQ — Inter ⭐⭐ (@Inter_en) November 26, 2024 Inter Milan edged past RB Leipzig 1-0 in their Champions League clash on Tuesday, thanks to an own goal by Castello Lukeba. The narrow victory at the San Siro sees the Italian champions move to the top of the standings, remaining unbeaten in the league phase. The decisive moment came in the 27th minute when Federico Dimarco’s dangerous free kick caused havoc in Leipzig’s defence, forcing Lukeba to turn the ball into his net inadvertently. Inter maintained control for most of the match, creating a few chances to double their lead, but failed to capitalise. Leipzig’s struggles were evident as they offered little going forward, extending their winless run to five matches in the competition. The German side remains rooted at the bottom of the table with no points, facing an early exit. Inter’s win takes them to 13 points, one ahead of Barcelona, who defeated Brest 3-0. Liverpool and Real Madrid, set to face off on Wednesday, will look to challenge the top positions. With one match remaining, Inter are firmly in control of their destiny and edging closer to securing a top-eight finish. Bayer Leverkusen 5-0 RB Salzburg Was. Für. Ein. Abend. 🔥😮💨 🔙 #B04SAL 5:0 pic.twitter.com/UkefkbESQY — Bayer 04 Leverkusen (@bayer04fussball) November 26, 2024 Bayer Leverkusen reignited their Champions League campaign with a dominant 5-0 victory over RB Salzburg on Tuesday night. Florian Wirtz starred with a brace, and Xabi Alonso’s side made light work of their Austrian opponents at the BayArena. The home side stormed into an early lead. Wirtz opened the scoring from the penalty spot in the eighth minute after Samson Baidoo’s handball, and Alejandro Grimaldo doubled the advantage three minutes later with a superb free kick. Wirtz added his second just before the half-hour mark, weaving through Salzburg’s defence to slot home. After the break, Leverkusen maintained their intensity. Patrik Schick made it 4-0 midway through the second half, and Aleix Garcia completed the rout with a well-taken goal in the 72nd minute. Salzburg’s goalkeeper Alexander Schlager made several crucial saves to prevent an even heavier defeat. The win lifts Leverkusen to 10 points in the standings, putting them back on track for a top-eight finish. Meanwhile, Salzburg remain stuck on three points, having suffered their fourth loss in five games. Leverkusen’s attacking fluidity and defensive solidity will provide a massive boost as they prepare for their final league-phase fixtures. Sporting 1-5 Arsenal Putting on a show at Sporting 🌟 pic.twitter.com/Yi9MgRZEkl — Arsenal (@Arsenal) November 26, 2024 Arsenal delivered a commanding 5-1 victory over Sporting CP at the Jose Alvalade Stadium, making a bold statement in their Champions League campaign. The win propels the Gunners into the top eight of the league phase, signalling a return to their dominant form. From the outset, Arsenal overwhelmed the Portuguese champions. Gabriel Martinelli opened the scoring in the 7th minute, capitalising on a superb cross from Jurrien Timber, who was excellent throughout. Kai Havertz doubled the lead with a simple finish after Bukayo Saka’s clever assist. Gabriel Magalhaes made it 3-0 in first-half stoppage time, converting a well-rehearsed corner that left Sporting stunned. Despite a strong response from Sporting early in the second half, including Gonçalo Inacio’s goal from a corner, Arsenal regained control. Martin Odegaard’s relentless pressing earned a penalty, coolly converted by Saka, restoring Arsenal’s dominance. Leandro Trossard added a fifth with a header late on, capping off a comprehensive performance. Defensively, Arsenal were superb, nullifying Victor Gyokeres, Sporting’s in-form striker. The win showcases Arsenal’s growing confidence and momentum. With their fluid attack and solid defence back to their best, the Gunners are emerging as serious contenders in Europe once again. BSC Young Boys 1-6 Atalanta FULL TIME | Per notti come questa 🌌 Nights like these ✨ #UCL #YoungBoysAtalanta 1-6 FT #GoAtalantaGo ⚫️🔵 pic.twitter.com/6Ybd55PYAJ — Atalanta B.C. (@Atalanta_BC) November 26, 2024 Charles De Ketelaere put on a masterclass as Atalanta crushed Young Boys 6-1 in the Champions League on Tuesday, underlining their attacking prowess. The Belgian forward was the star of the night, contributing three assists and scoring twice in a scintillating display. Atalanta wasted no time, with De Ketelaere setting up Mateo Retegui to open the scoring in the 9th minute. Although Silvere Ganvoula equalised for Young Boys just two minutes later, the visitors quickly regained control. De Ketelaere restored Atalanta’s lead with a well-taken goal in the 28th minute and turned provider again three minutes later, delivering an assist to Sead Kolasinac for a third. The first-half onslaught continued as Retegui netted his second in the 39th minute, once again assisted by De Ketelaere, as the Italian striker made the most of a perfectly weighted pass. Atalanta carried a commanding 4-1 lead into the break. The dominance resumed after halftime, with De Ketelaere adding a fifth goal in the 56th minute. His low shot from the edge of the box took a deflection, leaving the Young Boys keeper helpless. Substituted in the 75th minute to a standing ovation, De Ketelaere had already sealed his status as the man of the match. Lazar Samardzic rounded off the rout with a stoppage-time goal, ensuring Atalanta’s emphatic victory. Click for more latest Football news . Also get top headlines and latest news from India and around the world at News9. Nillohit Bagchi is enthusiastic young football journalist with a keen eye for detail, delivering fresh insights and dynamic coverage of global matches.
Prosperity Bancshares director Leah Henderson sells $91,564 in stock
Shares of Biohaven Pharmaceutical Holding Company ($BHVN) rose 2% on Monday afternoon, reversing early losses, while rival Scholar Rock Holding Corp. ($SRRK) surged over 30% to three-year highs after Biohaven’s spinal muscular atrophy (SMA) trial failed to meet its primary endpoint. Biohaven’s RESILIENT SMA study found that its treatment, taldefgrobep alfa, showed clinically meaningful motor function improvements at all time points on the Motor Function Measurement-32 (MFM-32) scale. However, the primary endpoint — statistical separation from placebo at 48 weeks — was not achieved. Last month, Scholar Rock achieved the primary endpoint in the company's own Phase 3 trial of apitegromab in SMA patients. JPMorgan deemed the trial setup “high in risk” and noted that many investors had not attributed significant value to the program, minimizing downside to Biohaven’s stock. The brokerage called the setback a “net positive” for Scholar Rock, as it removes near-term competition from another myostatin inhibitor. RBC Capital lowered its price target for Biohaven to $58 from $66 but maintained an ‘Outperform’ rating, citing favorable trends Biohaven plans to discuss with the FDA. Meanwhile, Jefferies pointed out that Scholar Rock now appears as a “cleaner story” with a clearer path to SMA market dominance and reiterated its $50 price target on SRRK. Truist raised its price target for Scholar Rock to $45 from $36, emphasizing its strengthened position in SMA and increasing its peak sales forecast for apitegromab to $1.5 billion. Wedbush also raised its target to $47 from $40, highlighting apitegromab as the likely first-to-market agent in its class with potential approval as early as Q4 2025. However, H.C. Wainwright maintained a ‘Buy’ rating on Biohaven, citing a positive signal for taldefgrobep alfa in reducing body fat mass, hinting at potential use in obesity treatment. The firm sees this as a possible pivot for Biohaven despite the SMA trial setback. On Stocktwits, sentiment for Scholar Rock turned ‘extremely bullish,’ while Biohaven saw a shift to ‘bearish’ amid heightened message activity. Biohaven was among the top 20 trending symbols by early afternoon. Scholar Rock has also generated interest for its ongoing Phase 2 trial targeting muscle preservation in patients experiencing rapid weight loss from GLP-1 weight-loss drugs, a burgeoning market. Spinal muscular atrophy, a rare neuromuscular disease affecting 30,000–35,000 people in the U.S. and Europe, presents a significant market opportunity. Year-to-date, Scholar Rock’s stock has risen over 120%, while Biohaven shares have gained 11%. For updates and corrections email newsroom[at]stocktwits[dot]com. Harris dismisses ‘project fear’ approach to Sinn FeinTesla stock lower as UBS says 'animal spirits' rather than fundamentals driving monster rally IWV Burros compete at Valley Youth Football League Super BowlLAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. “As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It’s an honor for General Motors and Cadillac to join the world’s premier racing series, and we’re committed to competing with passion and integrity to elevate the sport for race fans around the world," GM President Mark Reuss said. "This is a global stage for us to demonstrate GM’s engineering expertise and technology leadership at an entirely new level.” The approval ends years of wrangling that launched a U.S. Justice Department investigation into why Colorado-based Liberty Media, the commercial rights holder of F1, would not approve the team initially started by Michael Andretti. Andretti in September stepped aside from leading his namesake organization, so the 11th team will be called Cadillac F1 and be run by new Andretti Global majority owners Dan Towriss and Mark Walter. The team will use Ferrari engines its first two years until GM has a Cadillac engine built for competition in time for the 2028 season. Towriss is the the CEO and president of Group 1001 and entered motorsports via Andretti's IndyCar team when he signed on financial savings platform Gainbridge as a sponsor. Towriss is now a major part of the motorsports scene with ownership stakes in both Spire Motorsports' NASCAR team and Wayne Taylor Racing's sports car team. Walter is the chief executive of financial services firm Guggenheim Partners and the controlling owner of both the World Series champion Los Angeles Dodgers and Premier League club Chelsea. “We’re excited to partner with General Motors in bringing a dynamic presence to Formula 1," Towriss said. "Together, we’re assembling a world-class team that will embody American innovation and deliver unforgettable moments to race fans around the world.’’ Mario Andretti, the 1978 F1 world champion, will have an ambassador role with Cadillac F1. But his son, Michael, will have no official position with the organization now that he has scaled back his involvement with Andretti Global. The approval has been in works for weeks but was held until after last weekend's Las Vegas Grand Prix to not overshadow the showcase event of the Liberty Media portfolio. Max Verstappen won his fourth consecutive championship in Saturday night's race, the third and final stop in the United States for the top motorsports series in the world. Grid expansion in F1 is both infrequent and often unsuccessful. Four teams were granted entries in 2010 that should have pushed the grid to 13 teams and 26 cars for the first time since 1995. One team never made it to the grid and the other three had vanished by 2017. There is only one American team on the current F1 grid — owned by California businessman Gene Haas — but it is not particularly competitive and does not field American drivers. Andretti’s dream was to field a truly American team with American drivers. The fight to add this team has been going on for three-plus years and F1 initially denied the application despite approval from F1 sanctioning body FIA . The existing 10 teams, who have no voice in the matter, also largely opposed expansion because of the dilution in prize money and the billions of dollars they’ve already invested in the series. Andretti in 2020 tried and failed to buy the existing Sauber team. From there, he applied for grid expansion and partnered with GM, the top-selling manufacturer in the United States. The inclusion of GM was championed by the FIA and president Mohammed Ben Sulayem, who said Michael Andretti’s application was the only one of seven applicants to meet all required criteria to expand F1’s current grid. “General Motors is a huge global brand and powerhouse in the OEM world and is working with impressive partners," Ben Sulayem said Monday. "I am fully supportive of the efforts made by the FIA, Formula 1, GM and the team to maintain dialogue and work towards this outcome of an agreement in principle to progress this application." Despite the FIA's acceptance of Andretti and General Motors from the start, F1 wasn't interested in Andretti — but did want GM. At one point, F1 asked GM to find another team to partner with besides Andretti. GM refused and F1 said it would revisit the Andretti application if and when Cadillac had an engine ready to compete. “Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024,” F1 said in a statement. “Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the 11th team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process." Yet another major shift in the debate over grid expansion occurred earlier this month with the announced resignation of Liberty Media CEO Greg Maffei, who was largely believed to be one of the biggest opponents of the Andretti entry. “With Formula 1’s continued growth plans in the US, we have always believed that welcoming an impressive US brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport," Maffei said. "We credit the leadership of General Motors and their partners with significant progress in their readiness to enter Formula 1." AP auto racing: https://apnews.com/hub/auto-racingGreece-Cyprus Summit – Advancing Together: Greek and Cypriot ministers meet in Nicosia Republican firebrand Rep. Marjorie Taylor Greene has been tapped to chair a new congressional subcommittee aimed at eliminating government waste under the newly formed "Department of Government Efficiency," which is set to be led by Elon Musk and Vivek Ramaswamy -- and firing government employees could be part of her plan. House Oversight Committee Chairman James Comer announced the creation of the new GOP-controlled "Delivering on Government Efficiency (DOGE)" subcommittee in the next Congress, and Greene, a loyal supporter of President-elect Donald Trump, will chair it. Greene said in the new position, she will work to "identify and investigate the waste, corruption, and absolutely useless parts of our federal government." MORE: Trump transition live updates: Gaetz says he will not rejoin Congress "Our subcommittee will provide transparency and truth to the American people through hearings," she said in a statement. "The goal of DOGE is to bring accountability and GUT useless government agencies." Rep. Jamie Raskin, the ranking Democrat on the Oversight Committee, slammed the committee and Greene's involvement in it. "So now a noted student of American government, Rep. Marjorie Taylor Greene, will chair a subcommittee to work with two unvetted billionaires who stand to receive billions more in government contracts and subsidies from the government under Trump," Raskin said in a statement. The Georgia Republican has pledged to carry out Trump's agenda in the role and "rooted out every penny of waste and abuse" -- signaling that government employees' jobs could be on the chopping block. "In the private sector, if you're not doing a good job, you get fired. But for some reason, in government, bad employees—whether they're failing to do the job they were hired to do or working in roles that are no longer needed—never get fired," Greene wrote in a post on X on Thursday . "This is incredibly unfair to the hard-working taxpayers of our country, and it's about to change." Trump himself has made no secret of his plans to cut what he sees as government waste by calling for the dismantling for the Department of Education and selecting Cabinet picks who talk about abolishing entire agencies and firing tens of thousands of federal workers at a time. MORE: Can he do that? How Trump could try to break the federal government Helping in that effort could be the new Department of Government Efficiency -- helmed by Musk and Ramaswamy, both staunch allies of the president-elect. While DOGE will not be a federal agency in the U.S. government, Trump said it will provide advice and guidance "outside of government" and partner with the White House and Office of Management & Budget to "drive structural government reform." The president-elect did not detail how this new department would be funded. Lawmakers involved in the future subcommittee have already met with members of the White House DOGE team, including Ramaswamy, who support the Oversight Committee's endeavor and are already working together, according to a source. Ramaswamy posted on X that he is "looking forward" to working with Greene and with Congress in that effort. Greene's time in the House has been marked by several controversies -- including her involvement in a raucous House Oversight Committee meeting that included name calling and her plot to oust House Speaker Mike Johnson from the job earlier this year. She has been on the House Oversight Committee since 2023 -- but in 2021, the House voted to remove her from her assigned committees because of her record of making incendiary remarks ranging from allegedly supporting violence against House Speaker Nancy Pelosi and Democrats, to spreading baseless claims that mass school shootings were staged. ABC News' Will Steakin contributed to this report.S&P/TSX composite down nearly 250 points, U.S. stock markets also fall NEW YORK , Nov. 27, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The global advanced wound care market size is estimated to grow by USD 4.19 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 6.05% during the forecast period. Technological advancements in wound care products is driving market growth, with a trend towards increasing demand for combination dressings. However, high cost of wound treatments and advanced wound care products poses a challenge.Key market players include 3M Co., 4L Health Co. Ltd., Anika Therapeutics Inc., Cardinal Health Inc., Carilex Medical Inc., Coloplast AS, ConvaTec Group Plc, DeRoyal Industries Inc., Essity AB, Hollister Inc., Integra Lifesciences Corp., Johnson and Johnson Services Inc., Lohmann and Rauscher GmbH and Co. KG, Medline Industries LP, Medtronic Plc, Molnlycke Health Care AB, Organogenesis Holdings Inc., Paul Hartmann AG, Smith and Nephew plc, and Vericel Corp.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The Advanced Wound Care market is experiencing significant growth due to the rising prevalence of chronic diseases, particularly among the geriatric population. Diabetic foot ulcers are a major concern, leading to increased demand for innovative products like nanoparticle-based wound healing and gene therapy. ScienceDirect reports that surgical site infections and chronic wounds, including pressure ulcers and venous leg ulcers, result in high hospitalizations and healthcare expenditure. Companies like DuPont, JeNaCell, and ConvaTec offer advanced wound care products such as dressings, therapy devices, biologics, and matrices. Surgical procedures, medical tourism, and sports-related injuries also contribute to market growth. Strategic partnerships, manufacturing facilities, and supply network expansions are key strategies for market players. Innovative products include electronic skin patches, compression therapy, and debridement devices. Chronic nonhealing wounds, ischemia, bacterial contamination, and chronic inflammation are significant challenges. Obesity and diabetes are major risk factors for venous ulcers and diabetic ulcers. Home healthcare, Ambulatory Surgical Centers, and Wound Care Centres are emerging trends. Financial performance is monitored through strategy maps, focusing on revenue growth, market share, and product development. Advanced wound care market is witnessing significant growth due to the increasing popularity of antimicrobial agents in wound dressings. Silver, iodine, and honey are commonly used antimicrobial agents in advanced wound dressings. These dressings offer multiple benefits, combining physical and chemical properties for optimal functionality. They are suitable for both partial and full-thickness wounds. End-users prefer combination dressings due to their ease of use and availability. These dressings integrate distinct components into a single dressing, providing functions such as absorption, adhesion, and protection against bacteria. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges The Advanced Wound Care market faces significant challenges due to the rising prevalence of chronic diseases, particularly among the geriatric population. Diabetic foot ulcers are a major concern, leading to increased demand for innovative solutions like nanoparticle-based wound healing and gene therapy. ScienceDirect reports that surgical site infections also pose a challenge, driving the need for advanced medical devices and home healthcare services. Key players like DuPont, JeNaCell, and ConvaTec offer a range of wound care products, including dressings, therapy devices, and biologics. Hospitals and clinics in emerging economies are increasing their expenditure on chronic wounds, such as pressure ulcers and venous leg ulcers, leading to opportunities for manufacturers. However, challenges include managing infections, chronic inflammation, and ischemia, as well as ensuring bacterial burden management and pressure management. Innovative products, such as electronic skin patches and tracking devices, are gaining popularity for postoperative care and sports-related injuries. The supply network must adapt to meet the demand for these advanced wound care solutions, including surgical wounds, while managing the financials and implementing effective strategies. Ambulatory Surgical Centers and Wound Care Centers/Ambulatory Centers are also important players in this market. The advanced wound care market growth is influenced by the high cost of advanced wound care products. For example, Smith & Nephew's ALLEVYN foam dressing has a material cost per change of USD9.83 and a nursing cost per change of USD9.18 . Similarly, AxioBio's MaxioCel Wound Care Dressing For Ulcers costs USD50 per dressing. Frequent dressing changes are necessary for most patients, with alginate dressings requiring changes every two to three days, foam dressings every three to four days, hydrogel dressings every one to two days, hydrocolloid dressings every three to four days, and wound contact materials every four to seven days. These costs add up significantly, potentially limiting market expansion. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This advanced wound care market report extensively covers market segmentation by 1.1 Advanced wound dressings 1.2 Wound therapy devices 1.3 Wound care biologics 2.1 Hospitals 2.2 Clinics 2.3 Home healthcare 2.4 Others 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Advanced wound dressings- The advanced wound dressings market is driven by the increasing prevalence of chronic wounds and burns, the growing aging population, rising awareness about the clinical benefits of advanced wound dressings, and the increasing number of surgical procedures. The moist wound dressings segment, which includes alginate, collagen, foam, hydrocolloid, hydrogel, wound contact layer, and film dressings, dominates the market due to its ability to promote fast healing, maintain a hydrated environment, and prevent infection. Alginate dressings, derived from seaweed, are highly absorbent and non-adhesive, making them easy to remove and painless for patients. Collagen dressings, derived from animal sources, stimulate the growth of new collagen and promote quick recovery. Foam dressings provide a moist environment for quick healing and are available in various compositions and sizes. Hydrocolloid dressings maintain moisture in wound treatment and are commonly used in difficult-to-dress areas. Hydrogel dressings provide a moist wound environment for cell migration and accelerate healing. Wound contact layer dressings protect the tissues from bacterial attacks and are absorbent. Film dressings protect the skin in pressure spots and promote wound healing. Antimicrobial wound dressings, which include silver, iodine, honey, and zinc dressings, eliminate or prevent bacterial growth and are used to treat localized wound infections. The market is expected to grow rapidly during the forecast period due to the increasing adoption of advanced wound dressings, the focus on reducing hospital-acquired infections, and the rising preference for minimal and non-invasive procedures. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Advanced Wound Care market encompasses innovative technologies and treatments for managing chronic wounds, including diabetic foot ulcers and pressure ulcers. Chronic diseases, particularly in the geriatric population, contribute significantly to the prevalence of these wounds. ScienceDirect reports that chronic wounds affect over 6 million people in the US alone. Nanoparticle-based wound healing and gene therapy are emerging areas of research for advanced wound care. Home healthcare and MEA (Medical Equipment and Supplies) companies play crucial roles in providing wound care solutions. DuPont and JeNaCell are among the notable players in the market for wound care products, which include wound dressings, grafts, matrices, and surgical procedures. Surgical site infections, venous ulcers, and diabetic ulcers are common types of chronic wounds. Financial growth in the advanced wound care market is driven by increasing healthcare expenditure, the rising number of hospitals and clinics, and the growing demand for medical devices. Emerging economies offer significant opportunities for market expansion. Strategies for market success include product innovation, partnerships, and expanding reach into emerging markets. Market Research Overview The Advanced Wound Care market encompasses innovative technologies and treatments for managing various types of chronic wounds, including diabetic foot ulcers, pressure ulcers, surgical site infections, and venous ulcers. Chronic diseases, particularly diabetes and obesity, are major contributors to the rising prevalence of chronic wounds. The geriatric population is another significant factor, as they are more susceptible to wounds due to aging and comorbidities. ScienceDirect reports that nanoparticle-based wound healing and gene therapy are emerging areas in advanced wound care. Home healthcare, MEA (Medical Equipment and Supplies) companies, and Ambulatory Surgical Centers (ASCs) are increasingly adopting innovative products such as wound care kits, therapeutic devices, biologics, and extracellular matrix substitutes. Surgical procedures, plastic surgery, and medical tourism contribute to surgical wounds, which can lead to chronic nonhealing wounds. Hospitals, clinics, and healthcare expenditure continue to drive the market for wound care products, including dressings, grafts, matrices, and monitoring devices. The supply network includes key players like DuPont, JeNaCell, and ConvaTec, offering a range of products and services, from dressing and therapy devices to biologics and wound care centers. Innovative products include electronic skin patches, tracking devices, compression pressure monitoring, point-of-care imaging devices, and bioelectronic devices for debridement, pressure management, and bacterial burden management. Financial performance, strategy maps, and manufacturing facilities are essential aspects of the advanced wound care market, with companies focusing on cost-effective production and competitive pricing while maintaining quality and innovation. Emerging economies offer significant growth opportunities due to increasing healthcare expenditure and a large patient population. In summary, the advanced wound care market is a dynamic and growing industry, driven by demographic trends, technological advancements, and increasing healthcare expenditure. Companies must navigate the complex supply network, regulatory landscape, and competitive landscape to succeed in this market. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Product Advanced Wound Dressings Wound Therapy Devices Wound Care Biologics End-user Hospitals Clinics Home Healthcare Others Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE TechnavioSaquon Barkley is the NFL's version of Shohei Ohtani: AnalysisPet passports for dogs, cats and ferrets to travel within UK ‘an outrage’ None Gippsland Backs Greyhound Track as Animal Welfare Groups Voice Ethical Concerns London, United Kingdom, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Tavia Acquisition Corp. (the “Company”) announced that the underwriters of its previously announced initial public offering of units have fully exercised their over-allotment option yesterday, resulting in the issuance of an additional 1,500,000 units at a public offering price of $10.00 per unit. After giving effect to the exercise of the option, an aggregate of 11,500,000 units have been issued in the initial public offering at an aggregate offering price of $115,000,000. The Company is strategically focused on sectors pivotal to advancing sustainability and innovation, including energy transition and critical materials, circular economy initiatives, and innovative agricultural and food technologies. Each unit consists of one ordinary share and one right entitling the holder thereof to receive one-tenth of one ordinary share upon the completion of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on the Nasdaq Global Market under the symbols “TAVI” and “TAVIR,” respectively. EarlyBirdCapital, Inc. served as the sole book-running manager of the offering. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission (the “SEC”) on December 2, 2024. The offering was being made only by means of a prospectus, copies of which may be obtained by contacting EarlyBirdCapital, Inc. at 366 Madison Avenue, 8 th Floor, New York, New York 10017, Attention: Syndicate Department, by telephone at 212-661-0200. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Tavia Acquisition Corp. Tavia Acquisition Corp. is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, or reorganization or engaging in any other similar business combination with one or more businesses or entities. The Company is led by Chief Executive Officer Kanat Mynzhanov and Chief Financial Officer Askar Mametov, along with independent directors, Christophe Charlier, Darrell Mays, and Marsha Kutkevich. The Company’s team brings substantial expertise in deal sourcing, investing, and operations. The Company may pursue a business combination with a target in any industry or geographic location it chooses, although it intends to primarily direct its attention on target businesses in North America and Europe focused on energy transition, the circular economy, and food technologies. The Company believes these areas are critical to addressing environmental challenges, demographic shifts, and the transition towards sustainable practices. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the initial public offering and the anticipated use of the proceeds thereof, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the risk factors section of the registration statement and the prospectus for the Company’s initial public offering. Copies of these documents can be accessed through the SEC’s website at www.sec.gov . No assurance can be given that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Media Contact: Tavia Acquisition Corp. info@tavia.co Rivalry Closes Non-Brokered Private Placement Of Approximately $2.0 MillionStock market today: Wall Street hits records despite tariff talk AJ Marotte’s 21 points leads Oregon State past Boston College as Beavers end 4-game losing streakIndiana tries to snap 3-game losing skid to Nebraska
